Apatinib combined with oral etoposide in patients as second- or later-line with triple negativebreast cancer: a phase II, single-arm, prospective study

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2018
This article has no abstract
Epistemonikos ID: ce40733a20cd7adbd6360a3cbebf1ffe883af098
First added on: Apr 07, 2025